Reviews Gengraf Capsules


No reviews yet.

Gengraf Capsules Drug Description
GENGRAF® Capsules
(cyclosporine capsules, USP [MODIFIED])

WARNING
Only physicians experienced in the management of systemic immunosuppressive therapy for the indicated disease should prescribe Gengraf® (cyclosporine capsules, USP [MODIFIED]). At doses used in solid organ transplantation, only physicians experienced in immunosuppressive therapy and management of organ transplant recipients should prescribe Gengraf®. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient.
Gengraf®, a systemic immunosuppressant, may increase the susceptibility to infection and the development of neoplasia. In kidney, liver, and heart transplant patients Gengraf® may be administered with other immunosuppressive agents. Increased susceptibility to infection and the possible development of lymphoma and other neoplasms may result from the increase in the degree of immunosuppression in transplant patients.


Gengraf® (cyclosporine capsules, USP [MODIFIED]) has increased bioavailability in comparison to Sandimmune®* (cyclosporine capsules, USP). Gengraf® and Sandimmune®* are not bioequivalent and cannot be used interchangeably without physician supervision. For a given trough concentration, cyclosporine exposure will be greater with Gengraf® than with Sandimmune®.* If a patient who is receiving exceptionally high doses of Sandimmune®* is converted to Gengraf®, particular caution should be exercised. Cyclosporine blood concentrations should be monitored in transplant and rheumatoid arthritis patients taking Gengraf® to avoid toxicity due to high concentrations. Dose adjustments should be made in transplant patients to minimize possible organ rejection due to low concentrations. Comparison of blood concentrations in the published literature with blood concentrations obtained using current assays must be done with detailed knowledge of the assay methods employed.


For Psoriasis Patients (see also BOXED WARNINGS above)
Psoriasis patients previously treated with PUVA and to a lesser extent, methotrexate or other immunosuppressive agents, UVB, coal tar, or radiation therapy, are at an increased risk of developing skin malignancies when taking Gengraf® (cyclosporine capsules, USP [MODIFIED]).
Cyclosporine, the active ingredient in Gengraf®, in recommended dosages, can cause systemic hypertension and nephrotoxicity. The risk increases with increasing dose and duration of cyclosporine therapy. Renal dysfunction, including structural kidney damage, is a potential consequence of cyclosporine, and therefore, renal function must be monitored during therapy.

DRUG DESCRIPTION



What are the possible side effects of cyclosporine (Gengraf, Neoral, Sandimmune)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

urinating less than usual or not at all;
drowsiness, confusion, mood changes, increased thirst;
swelling, weight gain, feeling short of breath;
blurred vision, headache or pain behind your eyes, sometimes...
Read All Potential Side Effects for Gengraf Capsules »




Gengraf ® (cyclosporine capsules, USP [MODIFIED]) is a modified oral formulation of cyclosporine that forms an aqueous dispersion in an aqueous environment.
Cyclosporine, the active principle in Gengraf®, is a cyclic polypeptide
immunosuppressant agent consisting of 11 amino acids. It is produced as a metabolite
by the fungus species Aphanocladium album.
Chemically, cyclosporine is designated as [R-[R*, R*-(E)]]-cyclic-(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-3-hydroxy-N,4-dimethyl-L-2-amino-6-octenoyl-L-a-amino-butyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl).
Gengraf® Capsules (cyclosporine capsules, USP [MODIFIED]) are available
in 25 mg and 100 mg strengths. Each 25 mg capsule contains: cyclosporine, 25
mg, alcohol, USP, absolute, 12.8% v/v (10.1% wt/vol.). Each 100 mg capsule contains:
cyclosporine, 100 mg, alcohol, USP, absolute, 12.8% v/v (10.1% wt/vol.).
Inactive Ingredients: FD&C Blue No. 2, gelatin NF, polyethylene
glycol NF, polyoxyl 35 castor oil NF, polysorbate 80 NF, propylene glycol USP,
sorbitan monooleate NF, titanium dioxide.
The chemical structure for cyclosporine USP is:







Last reviewed on RxList: 5/11/2009




Gengraf Capsules Drug Description
GENGRAF® Capsules
(cyclosporine capsules, USP [MODIFIED])

WARNING
Only physicians experienced in the management of systemic immunosuppressive therapy for the indicated disease should prescribe Gengraf® (cyclosporine capsules, USP [MODIFIED]). At doses used in solid organ transplantation, only physicians experienced in immunosuppressive therapy and management of organ transplant recipients should prescribe Gengraf®. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient.
Gengraf®, a systemic immunosuppressant, may increase the susceptibility to infection and the development of neoplasia. In kidney, liver, and heart transplant patients Gengraf® may be administered with other immunosuppressive agents. Increased susceptibility to infection and the possible development of lymphoma and other neoplasms may result from the increase in the degree of immunosuppression in transplant patients.


Gengraf® (cyclosporine capsules, USP [MODIFIED]) has increased bioavailability in comparison to Sandimmune®* (cyclosporine capsules, USP). Gengraf® and Sandimmune®* are not bioequivalent and cannot be used interchangeably without physician supervision. For a given trough concentration, cyclosporine exposure will be greater with Gengraf® than with Sandimmune®.* If a patient who is receiving exceptionally high doses of Sandimmune®* is converted to Gengraf®, particular caution should be exercised. Cyclosporine blood concentrations should be monitored in transplant and rheumatoid arthritis patients taking Gengraf® to avoid toxicity due to high concentrations. Dose adjustments should be made in transplant patients to minimize possible organ rejection due to low concentrations. Comparison of blood concentrations in the published literature with blood concentrations obtained using current assays must be done with detailed knowledge of the assay methods employed.


For Psoriasis Patients (see also BOXED WARNINGS above)
Psoriasis patients previously treated with PUVA and to a lesser extent, methotrexate or other immunosuppressive agents, UVB, coal tar, or radiation therapy, are at an increased risk of developing skin malignancies when taking Gengraf® (cyclosporine capsules, USP [MODIFIED]).
Cyclosporine, the active ingredient in Gengraf®, in recommended dosages, can cause systemic hypertension and nephrotoxicity. The risk increases with increasing dose and duration of cyclosporine therapy. Renal dysfunction, including structural kidney damage, is a potential consequence of cyclosporine, and therefore, renal function must be monitored during therapy.

DRUG DESCRIPTION



What are the possible side effects of cyclosporine (Gengraf, Neoral, Sandimmune)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

urinating less than usual or not at all;
drowsiness, confusion, mood changes, increased thirst;
swelling, weight gain, feeling short of breath;
blurred vision, headache or pain behind your eyes, sometimes...
Read All Potential Side Effects for Gengraf Capsules »




Gengraf ® (cyclosporine capsules, USP [MODIFIED]) is a modified oral formulation of cyclosporine that forms an aqueous dispersion in an aqueous environment.
Cyclosporine, the active principle in Gengraf®, is a cyclic polypeptide
immunosuppressant agent consisting of 11 amino acids. It is produced as a metabolite
by the fungus species Aphanocladium album.
Chemically, cyclosporine is designated as [R-[R*, R*-(E)]]-cyclic-(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-3-hydroxy-N,4-dimethyl-L-2-amino-6-octenoyl-L-a-amino-butyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl).
Gengraf® Capsules (cyclosporine capsules, USP [MODIFIED]) are available
in 25 mg and 100 mg strengths. Each 25 mg capsule contains: cyclosporine, 25
mg, alcohol, USP, absolute, 12.8% v/v (10.1% wt/vol.). Each 100 mg capsule contains:
cyclosporine, 100 mg, alcohol, USP, absolute, 12.8% v/v (10.1% wt/vol.).
Inactive Ingredients: FD&C Blue No. 2, gelatin NF, polyethylene
glycol NF, polyoxyl 35 castor oil NF, polysorbate 80 NF, propylene glycol USP,
sorbitan monooleate NF, titanium dioxide.
The chemical structure for cyclosporine USP is:







Last reviewed on RxList: 5/11/2009




Gengraf Capsules Drug Description
GENGRAF® Capsules
(cyclosporine capsules, USP [MODIFIED])

WARNING
Only physicians experienced in the management of systemic immunosuppressive therapy for the indicated disease should prescribe Gengraf® (cyclosporine capsules, USP [MODIFIED]). At doses used in solid organ transplantation, only physicians experienced in immunosuppressive therapy and management of organ transplant recipients should prescribe Gengraf®. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient.
Gengraf®, a systemic immunosuppressant, may increase the susceptibility to infection and the development of neoplasia. In kidney, liver, and heart transplant patients Gengraf® may be administered with other immunosuppressive agents. Increased susceptibility to infection and the possible development of lymphoma and other neoplasms may result from the increase in the degree of immunosuppression in transplant patients.


Gengraf® (cyclosporine capsules, USP [MODIFIED]) has increased bioavailability in comparison to Sandimmune®* (cyclosporine capsules, USP). Gengraf® and Sandimmune®* are not bioequivalent and cannot be used interchangeably without physician supervision. For a given trough concentration, cyclosporine exposure will be greater with Gengraf® than with Sandimmune®.* If a patient who is receiving exceptionally high doses of Sandimmune®* is converted to Gengraf®, particular caution should be exercised. Cyclosporine blood concentrations should be monitored in transplant and rheumatoid arthritis patients taking Gengraf® to avoid toxicity due to high concentrations. Dose adjustments should be made in transplant patients to minimize possible organ rejection due to low concentrations. Comparison of blood concentrations in the published literature with blood concentrations obtained using current assays must be done with detailed knowledge of the assay methods employed.


For Psoriasis Patients (see also BOXED WARNINGS above)
Psoriasis patients previously treated with PUVA and to a lesser extent, methotrexate or other immunosuppressive agents, UVB, coal tar, or radiation therapy, are at an increased risk of developing skin malignancies when taking Gengraf® (cyclosporine capsules, USP [MODIFIED]).
Cyclosporine, the active ingredient in Gengraf®, in recommended dosages, can cause systemic hypertension and nephrotoxicity. The risk increases with increasing dose and duration of cyclosporine therapy. Renal dysfunction, including structural kidney damage, is a potential consequence of cyclosporine, and therefore, renal function must be monitored during therapy.

DRUG DESCRIPTION



What are the possible side effects of cyclosporine (Gengraf, Neoral, Sandimmune)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

urinating less than usual or not at all;
drowsiness, confusion, mood changes, increased thirst;
swelling, weight gain, feeling short of breath;
blurred vision, headache or pain behind your eyes, sometimes...
Read All Potential Side Effects for Gengraf Capsules »




Gengraf ® (cyclosporine capsules, USP [MODIFIED]) is a modified oral formulation of cyclosporine that forms an aqueous dispersion in an aqueous environment.
Cyclosporine, the active principle in Gengraf®, is a cyclic polypeptide
immunosuppressant agent consisting of 11 amino acids. It is produced as a metabolite
by the fungus species Aphanocladium album.
Chemically, cyclosporine is designated as [R-[R*, R*-(E)]]-cyclic-(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-3-hydroxy-N,4-dimethyl-L-2-amino-6-octenoyl-L-a-amino-butyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl).
Gengraf® Capsules (cyclosporine capsules, USP [MODIFIED]) are available
in 25 mg and 100 mg strengths. Each 25 mg capsule contains: cyclosporine, 25
mg, alcohol, USP, absolute, 12.8% v/v (10.1% wt/vol.). Each 100 mg capsule contains:
cyclosporine, 100 mg, alcohol, USP, absolute, 12.8% v/v (10.1% wt/vol.).
Inactive Ingredients: FD&C Blue No. 2, gelatin NF, polyethylene
glycol NF, polyoxyl 35 castor oil NF, polysorbate 80 NF, propylene glycol USP,
sorbitan monooleate NF, titanium dioxide.
The chemical structure for cyclosporine USP is:







Last reviewed on RxList: 5/11/2009




Gengraf Capsules Drug Description
GENGRAF® Capsules
(cyclosporine capsules, USP [MODIFIED])

WARNING
Only physicians experienced in the management of systemic immunosuppressive therapy for the indicated disease should prescribe Gengraf® (cyclosporine capsules, USP [MODIFIED]). At doses used in solid organ transplantation, only physicians experienced in immunosuppressive therapy and management of organ transplant recipients should prescribe Gengraf®. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient.
Gengraf®, a systemic immunosuppressant, may increase the susceptibility to infection and the development of neoplasia. In kidney, liver, and heart transplant patients Gengraf® may be administered with other immunosuppressive agents. Increased susceptibility to infection and the possible development of lymphoma and other neoplasms may result from the increase in the degree of immunosuppression in transplant patients.


Gengraf® (cyclosporine capsules, USP [MODIFIED]) has increased bioavailability in comparison to Sandimmune®* (cyclosporine capsules, USP). Gengraf® and Sandimmune®* are not bioequivalent and cannot be used interchangeably without physician supervision. For a given trough concentration, cyclosporine exposure will be greater with Gengraf® than with Sandimmune®.* If a patient who is receiving exceptionally high doses of Sandimmune®* is converted to Gengraf®, particular caution should be exercised. Cyclosporine blood concentrations should be monitored in transplant and rheumatoid arthritis patients taking Gengraf® to avoid toxicity due to high concentrations. Dose adjustments should be made in transplant patients to minimize possible organ rejection due to low concentrations. Comparison of blood concentrations in the published literature with blood concentrations obtained using current assays must be done with detailed knowledge of the assay methods employed.


For Psoriasis Patients (see also BOXED WARNINGS above)
Psoriasis patients previously treated with PUVA and to a lesser extent, methotrexate or other immunosuppressive agents, UVB, coal tar, or radiation therapy, are at an increased risk of developing skin malignancies when taking Gengraf® (cyclosporine capsules, USP [MODIFIED]).
Cyclosporine, the active ingredient in Gengraf®, in recommended dosages, can cause systemic hypertension and nephrotoxicity. The risk increases with increasing dose and duration of cyclosporine therapy. Renal dysfunction, including structural kidney damage, is a potential consequence of cyclosporine, and therefore, renal function must be monitored during therapy.

DRUG DESCRIPTION



What are the possible side effects of cyclosporine (Gengraf, Neoral, Sandimmune)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

urinating less than usual or not at all;
drowsiness, confusion, mood changes, increased thirst;
swelling, weight gain, feeling short of breath;
blurred vision, headache or pain behind your eyes, sometimes...
Read All Potential Side Effects for Gengraf Capsules »




Gengraf ® (cyclosporine capsules, USP [MODIFIED]) is a modified oral formulation of cyclosporine that forms an aqueous dispersion in an aqueous environment.
Cyclosporine, the active principle in Gengraf®, is a cyclic polypeptide
immunosuppressant agent consisting of 11 amino acids. It is produced as a metabolite
by the fungus species Aphanocladium album.
Chemically, cyclosporine is designated as [R-[R*, R*-(E)]]-cyclic-(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-3-hydroxy-N,4-dimethyl-L-2-amino-6-octenoyl-L-a-amino-butyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl).
Gengraf® Capsules (cyclosporine capsules, USP [MODIFIED]) are available
in 25 mg and 100 mg strengths. Each 25 mg capsule contains: cyclosporine, 25
mg, alcohol, USP, absolute, 12.8% v/v (10.1% wt/vol.). Each 100 mg capsule contains:
cyclosporine, 100 mg, alcohol, USP, absolute, 12.8% v/v (10.1% wt/vol.).
Inactive Ingredients: FD&C Blue No. 2, gelatin NF, polyethylene
glycol NF, polyoxyl 35 castor oil NF, polysorbate 80 NF, propylene glycol USP,
sorbitan monooleate NF, titanium dioxide.
The chemical structure for cyclosporine USP is:







Last reviewed on RxList: 5/11/2009




Gengraf Capsules Drug Description
GENGRAF® Capsules
(cyclosporine capsules, USP [MODIFIED])

WARNING
Only physicians experienced in the management of systemic immunosuppressive therapy for the indicated disease should prescribe Gengraf® (cyclosporine capsules, USP [MODIFIED]). At doses used in solid organ transplantation, only physicians experienced in immunosuppressive therapy and management of organ transplant recipients should prescribe Gengraf®. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient.
Gengraf®, a systemic immunosuppressant, may increase the susceptibility to infection and the development of neoplasia. In kidney, liver, and heart transplant patients Gengraf® may be administered with other immunosuppressive agents. Increased susceptibility to infection and the possible development of lymphoma and other neoplasms may result from the increase in the degree of immunosuppression in transplant patients.


Gengraf® (cyclosporine capsules, USP [MODIFIED]) has increased bioavailability in comparison to Sandimmune®* (cyclosporine capsules, USP). Gengraf® and Sandimmune®* are not bioequivalent and cannot be used interchangeably without physician supervision. For a given trough concentration, cyclosporine exposure will be greater with Gengraf® than with Sandimmune®.* If a patient who is receiving exceptionally high doses of Sandimmune®* is converted to Gengraf®, particular caution should be exercised. Cyclosporine blood concentrations should be monitored in transplant and rheumatoid arthritis patients taking Gengraf® to avoid toxicity due to high concentrations. Dose adjustments should be made in transplant patients to minimize possible organ rejection due to low concentrations. Comparison of blood concentrations in the published literature with blood concentrations obtained using current assays must be done with detailed knowledge of the assay methods employed.


For Psoriasis Patients (see also BOXED WARNINGS above)
Psoriasis patients previously treated with PUVA and to a lesser extent, methotrexate or other immunosuppressive agents, UVB, coal tar, or radiation therapy, are at an increased risk of developing skin malignancies when taking Gengraf® (cyclosporine capsules, USP [MODIFIED]).
Cyclosporine, the active ingredient in Gengraf®, in recommended dosages, can cause systemic hypertension and nephrotoxicity. The risk increases with increasing dose and duration of cyclosporine therapy. Renal dysfunction, including structural kidney damage, is a potential consequence of cyclosporine, and therefore, renal function must be monitored during therapy.

DRUG DESCRIPTION



What are the possible side effects of cyclosporine (Gengraf, Neoral, Sandimmune)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

urinating less than usual or not at all;
drowsiness, confusion, mood changes, increased thirst;
swelling, weight gain, feeling short of breath;
blurred vision, headache or pain behind your eyes, sometimes...
Read All Potential Side Effects for Gengraf Capsules »




Gengraf ® (cyclosporine capsules, USP [MODIFIED]) is a modified oral formulation of cyclosporine that forms an aqueous dispersion in an aqueous environment.
Cyclosporine, the active principle in Gengraf®, is a cyclic polypeptide
immunosuppressant agent consisting of 11 amino acids. It is produced as a metabolite
by the fungus species Aphanocladium album.
Chemically, cyclosporine is designated as [R-[R*, R*-(E)]]-cyclic-(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-3-hydroxy-N,4-dimethyl-L-2-amino-6-octenoyl-L-a-amino-butyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl).
Gengraf® Capsules (cyclosporine capsules, USP [MODIFIED]) are available
in 25 mg and 100 mg strengths. Each 25 mg capsule contains: cyclosporine, 25
mg, alcohol, USP, absolute, 12.8% v/v (10.1% wt/vol.). Each 100 mg capsule contains:
cyclosporine, 100 mg, alcohol, USP, absolute, 12.8% v/v (10.1% wt/vol.).
Inactive Ingredients: FD&C Blue No. 2, gelatin NF, polyethylene
glycol NF, polyoxyl 35 castor oil NF, polysorbate 80 NF, propylene glycol USP,
sorbitan monooleate NF, titanium dioxide.
The chemical structure for cyclosporine USP is:







Last reviewed on RxList: 5/11/2009





Other reviews about Gengraf Capsules on wordpress

HONESTY IS SUCH A LONELY WORD
  by shakira
  This is an essay written by my eldest daughter some time ago when she was 13, she is 14 now. What I really want to share […]


Gleevec 2 (in english)
  by Alexandre Nasiasene
Generic Name: imatinib (oral) (im MA ta nib) What is the most important information I should know about Gleevec? Do not use this medication without telling your doctor if you […]


UK: New Diet Pill Goes On Sale: INFO On Side Effects
  by Citizen's Free Press: Ireland
By J. P. Anderson: A diet pill which claims to flush out 25 per cent of the fat from food is being made available over the counter in Britain […]


Americans Need Help Getting Meds- How to Get Free or Reduced Needed RX medications
  by paganmedia
Thanks to USA federal government incentives, pharmaceutical companies may provide free prescription medicines if : Sourced and Submitted: By Lady Paradise ~ With much appreciated thanks on this […]


but before she could
  by czjupmosysajorn
I dont want any of her old pears and things; my cooking will turn out well, and Ill have a splendid dinner; see if I dont! Her voice […]


The dying Englishman smiled
  by jkildeljitbprv


Did you know poultry bled that e
  by rrnvjvacwyzrfk
Lie down and sleep afresh, Sahib. Then he rolled over and raised himself unsteadily on hands and knees. Darzee was a featherbrained little fellow who could never […]


With his head hunched low he travelled
  by fyvroxevivyhp
I will suppose it to be one of those afternoons, when all has gone smoothly and pleasantly, in school. Feels like it was full of gold bricks. When […]


_Good Humours_ sub editor sto
  by nofpiqdifkhar
The pronunciation of names will be found in the Index. Under the disadvantages, indeed, which both have had, is it not wonderful that they should be what they […]


To want to nail me to a card
  by aindhgutdvcsa
Although the main peduncle circumnutated, and described one large and [page 224] two smaller ellipses in the course of 24 h. The pain in his ear startled […]



Other reviews about Gengraf Capsules on web:

Learn about the prescription medication Gengraf Capsules (Cyclosporine Capsules), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Gengraf Capsules (Cyclosporine Capsules) Drug Information: Uses ...


DECEMBER 2000 (Gengraf ®) Cyclosporine. 25 mg, 100 mg capsules. Abbott Laboratories . All orders and prescriptions for cyclosporine products must specify the brand name as Gengraf â, ... Cyclosporine (Gengraf®)


Accurate, FDA approved Gengraf Capsules information for healthcare professionals and patients - brought to you by Drugs.com. Gengraf Capsules Official FDA information, side effects and uses.


All about Gengraf Capsules. View complete and up to date Gengraf information - part of the Drugs.com trusted medication database. Gengraf Capsules Facts and Comparisons at Drugs.com


Consumer information about the medication CYCLOSPORINE MICROEMULSION - ORAL CAPSULE (Gengraf, Neoral), includes side effects, drug interactions, recommended dosages, and storage ... CYCLOSPORINE MICROEMULSION - ORAL CAPSULE (Gengraf, Neoral) side ...


All about Gengraf Capsules. View complete and up to date Gengraf information - part of the Drugs.com trusted medication database. Gengraf Capsules Facts and Comparisons at - OrganizedWisdom Health


Learn about Gengraf Capsules (Cyclosporine Capsules) - Side Effects, Drug Interactions, Pictures, Patient Information on RxList Gengraf Capsules (Cyclosporine Capsules) Patient Drug Information ...


GENGRAF CAPSULES,uses:Arthritis, rheumatoid,Keratoconjunctivitis sicca,Psoriasis,Rejection, heart transplant, prophylaxis,Rejection, liver transplant, prophylaxis,Rejection, renal ... GENGRAF CAPSULES


Attention, chocolate lovers: You may not be able to help yourselves. Swiss and British scientists have linked the widespread love of chocolate to a chemical "signature" that ... GENGRAF® Capsules (cyclosporine capsules USP [MODIFIED]) Drug ...


Gengraf (Cyclosporine) Generic for Gengraf (Cyclosporine) is an immunosuppressant capsule used to prevent or treat organ rejection in transplant patients after a kidney, liver ... Generic Gengraf (Cyclosporine) 25/100mg - Side Efects and ...





Featured Reviews

Reviews Talwin Compound

Talwin Compound Drug Description DRUG DESCRIPTION TALWIN Compound is a combination of pentazocine hydrochloride, USP, equivalent to 12.5 mg base and aspirin, USP, 325 mg. Pentazocine is a member of the benzazocine series (also known...
Read More  |  Review This
Reviews Carbidopa

Lodosyn Drug Description LODOSYN® (carbidopa) Tablets When LODOSYN* (Carbidopa) is to be given to carbidopa-naive patients who are being treated with levodopa, the two drugs should be given at the same time, starting...
Read More  |  Review This
Reviews Erythromycin

Ilotycin Drug Description DRUG DESCRIPTION Ilotycin® (Erythromycin Ophthalmic Ointment, USP) belongs to the macrolide group of antibiotics. It is basic and readily forms a salt when combined with an acid. The base, as crystals or...
Read More  |  Review This
Reviews lacosamide Tablet and Injection

Vimpat Drug Description VIMPAT® (lacosamide) Tablet, Film Coated for Oral use VIMPAT® (lacosamide) Injection for Intravenous use DRUG DESCRIPTION What are the possible side effects of lacosamide (Vimpat)? Get emergency...
Read More  |  Review This
Reviews Tracleer

Tracleer Drug Description TRACLEER (bosentan) Tablets WARNING: RISKS OF LIVER INJURY and TERATOGENICITY Because of the risk of liver injury and birth defects, Tracleer is available only through a special restricted distribution...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....